Reporter brief
A Phase II Randomized Double-Blind Placebo-Controlled Study of Fisetin to Improve Physical Function in Breast Cancer Survivors
What happened
Trial registry update: RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract reports rationale and study design but contains no results, so effectiveness cannot be assessed from this material
- Even if results exist, a phase II trial cannot establish clinical benefit or whether fisetin works in the broader breast cancer survivor population
- The mechanism linking senescent cells to post-chemotherapy dysfunction remains theoretical in this specific population
Study design and sample
Rct; Human.
Women who have received chemotherapy for stage I-III breast cancer, described as postmenopausal in the rationale.
- Design
- Rct
- Sample
- —
- Journal
- Jonsson Comprehensive Cancer Center
- Published
- Jul 17, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.